NASDAQ : OKYO
OKYO Pharma Limited — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 1.5 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 78.72M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 77.14M |
| Enterprise Value | 56.55M |
Dates
| Measure | Value |
|---|
| Earnings Date | Jul 20, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 52.48M |
| Shares Outstanding | 52.48M |
| Shares Change (YoY) | -5.40% |
| Shares Change (QoQ) | -0.34% |
| Owned by Insiders (%) | 32.08% |
| Owned by Institutions (%) | 13.16% |
| Float | 27.94M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.25 |
| P/TBV Ratio | 6.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.43 |
| Quick Ratio | 2.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.93 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -263.78% |
| Return on Assets (ROA) | -43.09% |
| Return on Invested Capital (ROIC) | -156.57% |
| Return on Capital Employed (ROCE) | -68.91% |
| Weighted Average Cost of Capital (WACC) | 3.48% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.79M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 7,987 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.14 |
| 52-Week Price Change | -45.96% |
| 50-Day Moving Average | 1.44 |
| 200-Day Moving Average | 1.62 |
| Relative Strength Index (RSI) | 52.83 |
| Average Volume (20 Days) | 49,197 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 76,652 |
| Short Previous Month | 34,643 |
| Short % of Shares Out | 0.15% |
| Short % of Float | 0.27% |
| Short Ratio (days to cover) | 1.26 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -6.69M |
| Operating Income | -8.50M |
| Pretax Income | -8.94M |
| Net Income | -8.95M |
| EBITDA | -8.50M |
| EBIT | -8.50M |
| Earnings Per Share (EPS) | -$0.24 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 20.59M |
| Total Debt | n/a |
| Net Cash | 20.59M |
| Net Cash Per Share | $0.39 |
| Equity (Book Value) | 12.34M |
| Book Value Per Share | 0.24 |
| Working Capital | 12.33M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -5.94M |
| Capital Expenditures | -6,080 |
| Depreciation & Amortization | 1,820 |
| Net Borrowing | n/a |
| Free Cash Flow | -5.94M |
| FCF Per Share | -$0.11 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 5.40% |
| Shareholder Yield | n/a |
| Earnings Yield | -16.30% |
| FCF Yield | -7.70% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.33 |
| Price Target Difference | 466.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 22, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:65 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |